Healthcare is entering a new phase shaped by a market that moves faster and expects more, and as a result, the traditional playbooks for pharmaceutical success are starting to show their age: Clinical differentiation, HCP buy-in, and incremental gains in access no longer guarantee success in any therapy area.
At Pharma USA 2026, vendors, attendees, and speakers were focused on rewriting those playbooks for a new, high-speed commercial reality where access is engineered as carefully as the therapies themselves, and the gap between pharma developer and patient is closing rapidly.
The Definitive Healthcare team came together in Philadelphia to attend sessions, tune into keynotes, and hold conversations with industry insiders to get a closer look at the differentiators that are likely to determine commercial success in the pharmaceutical markets of today and tomorrow. Here’s what we learned.
1. Access is the new frontier for biopharma innovation
For much of the history of the pharmaceutical industry, innovation has focused primarily on molecules and, to a lesser extent, care models. During this year’s Pharma USA, keynotes covering topics ranging from obesity to opportunities in biosimilars showed that access is the new locus of innovation.
While effective therapies will always be the foundation of biopharma success, industry experts say the leaders in the modern market will be those who can get those therapies to patients fastest and at scale. This is especially true in the increasingly competitive obesity management space, as payer cuts to GLP-1 coverage threaten to hinder utilization and slow market growth.
The biosimilars market faces a similar tension: Even with clinically effective, lower-cost alternatives becoming more available due to regulatory shifts in favor of biosimilar development, adoption is lagging as structural and behavioral barriers persist.
On the journey from diagnosis to active therapy, patients have numerous off-ramps to noncompliance and/or prescription abandonment. Couple that with provider bottlenecks and payor delays, and pharma companies have every reason to design and control their access pathways as closely and carefully as the drugs they produce.
Multiple Pharma USA sessions suggested that parallel access infrastructure should be part of every developer’s playbook. By combining traditional payor- and provider-driven distribution pathways with direct-to-consumer, cash-pay, and digital sales, pharmaceutical companies can maximize access, affordability, and adherence.
2. Winning commercial models close the gap between pharma and patient
The answer to biopharma’s patient access question is “zero”—that is, there should be zero distance between pharmaceutical developer and the end patient, according to industry leaders at ZS, Nestle Health Science, Amgen, and Hone Health.
Stakeholders across the market have rising expectations for pharma: Patients want consumer-grade convenience; providers want real-time insights into behaviors, barriers, and outcomes; and payors want clear demonstrations of therapy value. Direct-to-consumer models that close the gap between pharmaceutical developer and patient aim to deliver for everyone involved.
By building commercial models that cater directly to patients rather than HCPs or payors, pharma companies can reap the benefits of continuous engagement, such as rapid access to near-real-time data, reduced distributary friction, and greater control over the patient journey from awareness through adherence. For patients and providers, that means faster access to therapy, more personalized care experiences, and a streamlined path to positive outcomes through compliance.
Shifting from a B2B2C model to a hybridized, direct-to-patient model will require pharma organizations to develop new skills, particularly around experience design, data infrastructure, and patient lifecycle management. But those that do are likely to be rewarded with increased patient loyalty, more favorable payor/provider relationships, and a steady stream of powerful insights that can further shape commercial strategy.
3. Speed is the new competitive moat
Want to beat the competition in biopharma? Just go faster.
Speed as a competitive differentiator is nothing new or novel, but the holistic impact of building speed across multiple functions within a pharma organization can’t be overstated, especially in a modern market where nearly every timeline—from R&D to commercialization to patient onboarding and beyond—is rapidly compressing.
At Pharma USA 2026, several sessions highlighted areas where speed makes an outsized difference:
- Launch timelines: Faster launches equate to stronger payor positioning and market share capture.
- Patient onboarding: Reducing time from diagnosis to therapy initiation accelerates revenue collection, improves patient outcomes and adherence, and strengthens provider/payor relationships.
- Insight generation: Companies that leverage real-time analytics rather than retrospective reporting can respond more quickly to emerging trends and unmet needs.
The keynote presentation “The Speed Imperative” examined biotech and digital health disruptors with time-to-market advantages, suggesting that speed in innovation and product launch was particularly critical for determining which organizations became first movers and shaped product categories, versus those that became followers and competed on price and access.
But speed doesn’t just come down to efficient processes; it’s a byproduct of data-driven strategy, operational discipline, and openness to new methods and models. While “slow” organizations retain traditional silos and rely on manual processes and legacy infrastructure because “it just works,” “fast” organizations lean on cross-functional decision-making and integrate real-time data with artificial intelligence (AI) to automate and streamline wherever possible.
4. AI is moving from assistive tool to autonomous decision engine
Among the data-obsessed Definitive Healthcare team, one idea rang out particularly loud and clear at Pharma USA 2026: The pharmaceutical industry is moving past backward-facing analytics.
Traditionally, analytical tools built on historical data have provided descriptive answers to the question, “What happened here?” Emerging AI systems—paired with real-world, and near-real-time data—are not only helping organizations determine why it happened and what they should do next, but even going as far as executing the next best actions autonomously.
Pharma leaders like Regeneron are employing AI tools with semantic layers that enable non-technical stakeholders to find answers to their complex questions instantly, eliminating the analyst bottleneck while retaining an auditable, data-backed record.
From field-level decision-making to HCP engagement strategies to launch execution, savvy pharma developers should seek opportunities to leverage AI for insight generation as well as action orchestration. But in order to get the most from AI, companies must seriously consider redesigning their organizational structures, cultures, and leadership styles for the high-velocity decision-making that AI enables.
Get the data to get ahead in pharma
Underpinning nearly every topic at Pharma USA 2026 was the value of up-to-date, carefully curated data.
Whether your organization is focused on improving access pathways, connecting with patients directly, building speed across functions, or getting more from AI, data is the fuel that powers the engines of efficiency and innovation.
Definitive Healthcare’s data and analytics platform combines all-payor claims and reference and affiliations datasets with powerful, AI-backed population, consumer, and market insights—and that’s just the tip of the iceberg.
See how Definitive Healthcare can help you find opportunities, navigate emerging headwinds, and make smarter, faster decisions. Sign up for a demo today.
You might also be interested in...
